• Accueil
• tpex
• The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer

The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer

4.8 (732) · € 17.50 · En Stock

Frontiers TTCC-2019-02: real-world evidence of first-line

Cetuximab, docetaxel, and cisplatin as first-line treatment in

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

Avelumab as neoadjuvant therapy in patients with urothelial non

The Lancet Oncology, January 2024, Volume 25, Issue 1, Pages 1-146

Induction chemotherapy with lobaplatin and fluorouracil versus

Radiotherapy plus cetuximab or cisplatin in human papillomavirus

Taking a Closer Look at Recurrent/Metastatic SCCHN - ppt download

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic

Frontiers Cetuximab-Containing Combinations in Locally Advanced

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

Frontiers Feasibility of Induction Docetaxel, Cisplatin, 5

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and